Ji Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ji Li has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Jianwei Wang
College of Basic Medicine, Heilongjiang University of Chinese Medicine, Harbin, China
2 shared publications Meiqiao Wang
Department of Pathology, Heilongjiang University of Chinese Medicine, Xiangfang, Harbin 150040, P.R. China
2 shared publicationsQiaomei Dai
Department of Pathology, Heilongjiang University of Chinese Medicine, Xiangfang, Harbin 150040, P.R. China
2 shared publications- Qiaomei Dai
Department of Pathology, Heilongjiang University of Chinese Medicine, Harbin, China
2 shared publications Yaozhang Li
Department of Pathology, Heilongjiang University of Chinese Medicine, Xiangfang, Harbin 150040, P.R. China
2 shared publicationsYu Yun
Department of Oncology, Traditional Chinese Medical Hospital of Siyang County, Jiangsu, China
2 shared publications
Latest Publications
- Open Access
- 26 February 2020
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 19 (4) , 3009-3016
TlR2 and TlR4 are involved in the treatment of rheumatoid arthritis synovial fibroblasts with a medicated serum of asarinin through inhibition of Th1/Th17 cytokines
Asarinin is one of the main active chemical components isolated from Xixin, a Chinese medicine. To investigate the role of asarinin in rheumatoid arthritis (RA), the present study investigated the effect of an asarinin‑medicated serum on human fibroblast‑like synoviocytes in vitro. An asarinin‑medicated serum was generated and analyzed by high‑performance liquid chromatography. Fibroblast‑like synoviocytes were isolated from patients with osteoarthritis and RA. The third generation of the rheumatoid synoviocytes was used in the experimental research and the third generation of osteoarthritic synoviocytes was used as control cells. Trypan blue staining was performed to detect the viability of RA synovial fibroblasts (RASFs). ELISA, reverse transcription‑quantitative (RT‑q) PCR and western blotting were also performed to detect the expression of various cytokines. Additionally, RT‑qPCR was employed to detect Toll‑like receptor (TLR) 2 and TLR4. The results revealed that medicated asarinin serum inhibited the viability of RASFs in a dose‑ and time‑dependent manner. The serum also suppressed the expression of interleukin (IL)‑17A, tumor necrosis factor‑α, interferon‑γ, IL‑6, TLR2 and TLR4. The inhibitory effect of asarinin drug serum on RASFs may be achieved by inhibition of T helper cell (Th)1/Th17 cytokines through suppression of TLR2 and TLR4.
- 26 February 2020
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 19 (4) , 3009-3016
Open AccessTlR2 and TlR4 are involved in the treatment of rheumatoid arthritis synovial fibroblasts with a medicated serum of asarinin through inhibition of Th1/Th17 cytokines
Asarinin is one of the main active chemical components isolated from Xixin, a Chinese medicine. To investigate the role of asarinin in rheumatoid arthritis (RA), the present study investigated the effect of an asarinin‑medicated serum on human fibroblast‑like synoviocytes in vitro. An asarinin‑medicated serum was generated and analyzed by high‑performance liquid chromatography. Fibroblast‑like synoviocytes were isolated from patients with osteoarthritis and RA. The third generation of the rheumatoid synoviocytes was used in the experimental research and the third generation of osteoarthritic synoviocytes was used as control cells. Trypan blue staining was performed to detect the viability of RA synovial fibroblasts (RASFs). ELISA, reverse transcription‑quantitative (RT‑q) PCR and western blotting were also performed to detect the expression of various cytokines. Additionally, RT‑qPCR was employed to detect Toll‑like receptor (TLR) 2 and TLR4. The results revealed that medicated asarinin serum inhibited the viability of RASFs in a dose‑ and time‑dependent manner. The serum also suppressed the expression of interleukin (IL)‑17A, tumor necrosis factor‑α, interferon‑γ, IL‑6, TLR2 and TLR4. The inhibitory effect of asarinin drug serum on RASFs may be achieved by inhibition of T helper cell (Th)1/Th17 cytokines through suppression of TLR2 and TLR4.
- Open Access
- 1 July 2019
- Published by Pharmaceutical Society of Japan in Biological and Pharmaceutical Bulletin
- Vol. 42 (7) , 1172-1178
Amelioration of CIA by Asarinin Is Associated to a Downregulation of TLR9/NF-κB and Regulation of Th1/Th2/Treg Expression
To study the role of asarinin on collagen-induced arthritis (CIA) and its treatment mechanism on dendritic cells (DCs) and T cells. Before the onset of arthritis, asarinin were given orally to CIA mouse. Macroscopic scoring and micrometer caliper measurement were used to assess arthritis. The occurrence of cartilage destruction and bone erosion were assessed by histology of knee. Sandwich ELISA and PCR were used to assess the level of cytokines in hindpaw and arthritic joint. The CD11c MicroBeads were employed to isolate CD11c+ cells from the spleen. Quantitative PCR was used to determine DCs surface molecules of spleen. Macroscopic score and the frequency of arthritis were inhibited by asarinin. Swelling of hindpaws, inflammatory cell infiltration in the synovium, cartilage destruction, and bone erosion were delayed with asarinin. Asarinin treatment suppressed the expression of Th1 cytokines and increased the levels of Th2 cytokines (IL-10), TGF-β and Foxp3 in the synovium and hindpaw, however T-bet mRNA levels in synovium decreased. Lower expression of TLR9 and NF-kB were found in DCs after asarinin treatment. There was no difference in the expression of ICAM-1, OX40-L, and 4-1BBL in spleen DCs between the asarinin group and model control group. Asarinin can treat CIA. TLR9/NF-κB pathway may be involved in the asarinin treatment of CIA by skewing the balance of Th1/Th2/Treg to a Th2 type.
- 1 July 2019
- Published by Pharmaceutical Society of Japan in Biological and Pharmaceutical Bulletin
- Vol. 42 (7) , 1172-1178
Open AccessAmelioration of CIA by Asarinin Is Associated to a Downregulation of TLR9/NF-κB and Regulation of Th1/Th2/Treg Expression
To study the role of asarinin on collagen-induced arthritis (CIA) and its treatment mechanism on dendritic cells (DCs) and T cells. Before the onset of arthritis, asarinin were given orally to CIA mouse. Macroscopic scoring and micrometer caliper measurement were used to assess arthritis. The occurrence of cartilage destruction and bone erosion were assessed by histology of knee. Sandwich ELISA and PCR were used to assess the level of cytokines in hindpaw and arthritic joint. The CD11c MicroBeads were employed to isolate CD11c+ cells from the spleen. Quantitative PCR was used to determine DCs surface molecules of spleen. Macroscopic score and the frequency of arthritis were inhibited by asarinin. Swelling of hindpaws, inflammatory cell infiltration in the synovium, cartilage destruction, and bone erosion were delayed with asarinin. Asarinin treatment suppressed the expression of Th1 cytokines and increased the levels of Th2 cytokines (IL-10), TGF-β and Foxp3 in the synovium and hindpaw, however T-bet mRNA levels in synovium decreased. Lower expression of TLR9 and NF-kB were found in DCs after asarinin treatment. There was no difference in the expression of ICAM-1, OX40-L, and 4-1BBL in spleen DCs between the asarinin group and model control group. Asarinin can treat CIA. TLR9/NF-κB pathway may be involved in the asarinin treatment of CIA by skewing the balance of Th1/Th2/Treg to a Th2 type.
- Open Access
- 7 March 2019
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2019, 1
Corrigendum to “Toll-Like Receptor 4–Myeloid Differentiation Primary Response Gene 88 Pathway Is Involved in the Shikonin Treatment of CIA by Regulating Treg/Th17 Expression”
[This corrects the article DOI: 10.1155/2018/2428546.].
- 7 March 2019
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2019, 1
Open AccessCorrigendum to “Toll-Like Receptor 4–Myeloid Differentiation Primary Response Gene 88 Pathway Is Involved in the Shikonin Treatment of CIA by Regulating Treg/Th17 Expression”
[This corrects the article DOI: 10.1155/2018/2428546.].
- Open Access
- 1 January 2018
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2018 (1) , 2428546
Toll‐Like Receptor 4–Myeloid Differentiation Primary Response Gene 88 Pathway Is Involved in the Shikonin Treatment of CIA by Regulating Treg/Th17 Expression
Objective. To investigate the effect of shikonin on (CIA) collagen‐induced arthritis and its influence and mechanism on the balance between Th17 cells and Treg cells. Methods. Three doses of shikonin were administered orally to mice before the onset of CIA, and celecoxib was used as positive control drug. The arthritis response was monitored visually by macroscopic scoring and hindpaw swelling. Histology of knee was used to assess the occurrence of cartilage destruction and bone erosion. Serum collagen type II (C II) antibody levels associated with CIA were assessed with ELISAs. RT‐PCR and quantitative PCR were employed to determine the mRNA expression of cytokines and TLRs in the surface of DCs in the patella with adjacent synovium and spleen in CIA. The expression of cytokines and transcription factors in the peripheral immune organs was tested by Western blotting. Results. Shikonin treatment suppressed the macroscopic score and incidence of arthritis. Swelling of hind paws, cartilage destruction, and serum anti‐C II concentration were delayed with shikonin when compared to controls. Shikonin treatment suppressed the arthritis in a dose‐dependent manner. Moreover, the expression of Th17 cytokines (IL‐17A) was greatly inhibited both in the synovium and spleen in treated groups compared with those in control groups. The mRNA and protein levels of IL‐10 and TGF‐β, however, were upregulated after shikonin treatment. The expression of Foxp3 in the synovium and spleen was upregulated, and the expression of ROR‐γt in the synovium and spleen was downregulated after shikonin treatment through RT‐PCR, quantitative PCR, and Western blotting. The DCs in the spleen of shikonin‐treated mice had lower expression of TLR4 and MyD88, and the expression of TLR2 and TLR9 in the spleen was not different between the two groups. Conclusion. Shikonin has anti‐inflammatory effects on CIA. Shikonin treatment can inhibit Th17 cytokines expression and induce Treg responses through inhibiting the activation of TLR4/MyD88 pathway.
- 1 January 2018
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2018 (1) , 2428546
Open AccessToll‐Like Receptor 4–Myeloid Differentiation Primary Response Gene 88 Pathway Is Involved in the Shikonin Treatment of CIA by Regulating Treg/Th17 Expression
Objective. To investigate the effect of shikonin on (CIA) collagen‐induced arthritis and its influence and mechanism on the balance between Th17 cells and Treg cells. Methods. Three doses of shikonin were administered orally to mice before the onset of CIA, and celecoxib was used as positive control drug. The arthritis response was monitored visually by macroscopic scoring and hindpaw swelling. Histology of knee was used to assess the occurrence of cartilage destruction and bone erosion. Serum collagen type II (C II) antibody levels associated with CIA were assessed with ELISAs. RT‐PCR and quantitative PCR were employed to determine the mRNA expression of cytokines and TLRs in the surface of DCs in the patella with adjacent synovium and spleen in CIA. The expression of cytokines and transcription factors in the peripheral immune organs was tested by Western blotting. Results. Shikonin treatment suppressed the macroscopic score and incidence of arthritis. Swelling of hind paws, cartilage destruction, and serum anti‐C II concentration were delayed with shikonin when compared to controls. Shikonin treatment suppressed the arthritis in a dose‐dependent manner. Moreover, the expression of Th17 cytokines (IL‐17A) was greatly inhibited both in the synovium and spleen in treated groups compared with those in control groups. The mRNA and protein levels of IL‐10 and TGF‐β, however, were upregulated after shikonin treatment. The expression of Foxp3 in the synovium and spleen was upregulated, and the expression of ROR‐γt in the synovium and spleen was downregulated after shikonin treatment through RT‐PCR, quantitative PCR, and Western blotting. The DCs in the spleen of shikonin‐treated mice had lower expression of TLR4 and MyD88, and the expression of TLR2 and TLR9 in the spleen was not different between the two groups. Conclusion. Shikonin has anti‐inflammatory effects on CIA. Shikonin treatment can inhibit Th17 cytokines expression and induce Treg responses through inhibiting the activation of TLR4/MyD88 pathway.